Novocure Ltd (NVCR NASDAQ) stock market data APIs
$10.8926
0.1(0.9%)
as of November 7, 2025
Try our APIs with
free plan!
Novocure Ltd Financial Data Overview
Price chart is built with
Anychart
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Prev. Close
10.8926
Open
10.9914
High
11.1844
Low
10.7533
52 wk Range
10.7-34.13
Market Cap
1 223 M
Shares Outstanding
112 M
Revenue
642 M
EPS
-0.33
Beta
0.826
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Novocure Ltd (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Novocure Ltd data using free add-ons & libraries
Get Novocure Ltd Fundamental Data
Novocure Ltd Fundamental data includes:
- Net Revenue: 642 M
- EBITDA: -159 287 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-23
- EPS/Forecast: -0.427
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Novocure Ltd News
New
NovoCure (NVCR) Valuation Discount Contrasts With Persistent Losses and Unprofitability Challenges
NovoCure (NVCR) is forecasting revenue growth of 15% per year, outpacing the US market average of 10.3%, but the company continues to post net losses and remains unprofitable. Over the past five years...
NovoCure Ltd (NVCR) Q3 2025 Earnings Call Highlights: Revenue Growth Amidst Challenges
This article first appeared on GuruFocus. Net Revenue: $167 million, an 8% increase from the third quarter last year. Gross Margin: 73%, reflecting the global rollout of HFE arrays and increased tari...
Novocure outlines four-indication expansion and profitability target for 2027 as GBM growth continues
Earnings Call Insights: Novocure Limited (NVCR) Q3 2025 MANAGEMENT VIEW * Executive Chairman William Doyle stated that Novocure is transitioning from a single indication company to a platform ther...
Compared to Estimates, NovoCure (NVCR) Q3 Earnings: A Look at Key Metrics
For the quarter ended September 2025, NovoCure (NVCR) reported revenue of $167.2 million, up 7.8% over the same period last year. EPS came in at -$0.33, compared to -$0.28 in the year-ago quarter. Th...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
